HER2 Support Group Forums - View Single Post - MCC-DM-1 trial closed

Joan M · 06-26-2008, 06:40 PM

Run,

Sloan directed me to St. Barnabas and to the Bronx.

Ilda Boholli is no longer at St. Barnabas even though she's listed as the contact, and I spoke instead with with Elyce Hirtler. After we spoke she talked to Dr. Michaelson and then called me back to say that the second segment of the trial is closed. That is, the sponsor Genentech met its quota of 100 and surpassed that by 10 for 110 idividuals. So none of the sites will be recruiting now for this part of the trial.

After I spoke to her, Dr. Modi, the study doctor at Sloan-Kettering, called me from some airport somewhere (what a great lady! And really nice, too!). She explained that the second segement of the trial is closed and that in the fall Sloan will be opening another segment but under more strict enrollment criteria. For this segment of the Phase II trial, patients will have had to progressed on Tykerb and Xeloda. As you probably know, the initial recruitment criteria called for progressing while taking only Herceptin.

Since I haven't taken either Tykerb or Xeloda, I would not be eligible, but some of the sisters (or brothers) on the board may want to look into the trial.

The trial is listed on the NIH website and the full copy of the trial shows all the locations where the trial is available.

Thanks much for all your support.

Joan

06-26-2008, 06:40 PM	#8
Joan M Senior Member Join Date: Oct 2007 Posts: 1,851	Run, Sloan directed me to St. Barnabas and to the Bronx. Ilda Boholli is no longer at St. Barnabas even though she's listed as the contact, and I spoke instead with with Elyce Hirtler. After we spoke she talked to Dr. Michaelson and then called me back to say that the second segment of the trial is closed. That is, the sponsor Genentech met its quota of 100 and surpassed that by 10 for 110 idividuals. So none of the sites will be recruiting now for this part of the trial. After I spoke to her, Dr. Modi, the study doctor at Sloan-Kettering, called me from some airport somewhere (what a great lady! And really nice, too!). She explained that the second segement of the trial is closed and that in the fall Sloan will be opening another segment but under more strict enrollment criteria. For this segment of the Phase II trial, patients will have had to progressed on Tykerb and Xeloda. As you probably know, the initial recruitment criteria called for progressing while taking only Herceptin. Since I haven't taken either Tykerb or Xeloda, I would not be eligible, but some of the sisters (or brothers) on the board may want to look into the trial. The trial is listed on the NIH website and the full copy of the trial shows all the locations where the trial is available. Thanks much for all your support. Joan __________________ Diagnosed stage 2b in July 2003 (2.3 cm, HER2+, ER-/PR-, 7+ nodes). Treated with mastectomy (with immediate DIEP flap reconstruction), AC + T/Herceptin (off label). Cancer advanced to lung in Jan. 2007 (1 cm nodule). Started Herceptin every 3 weeks. Lung wedge resection April 2007. Cancer recurred in lung April 2008. RFA of lung in August 2008. 2nd annual brain MRI in Oct. 2008 discovered 2.6 cm cystic tumor in left frontal lobe. Craniotomy Oct. 2008 (ER-/PR-/HER2-) followed by targeted radiation (IMRT). Coughing up blood Feb. 2009. Thoractomy July 2009 to cut out fungal ball of common soil fungus (aspergillus) that grew in the RFA cavity (most likely inhaled while gardening). No cancer, only fungus. Removal of tiny melanoma from upper left arm, plus sentinel lymph node biopsy in Feb. 2016. Guardant Health liquid biopsy in Feb. 2016 showed mutations in 4 subtypes of TP53. Repeat of Guardant Health biopsy in Jana. 2021 showed 3 TP53 mutations, BRCA1 mutation and CHEK2 mutation. Invitae genetic testing showed negative for all of these. Living with MBC since 2007. Stopped Herceptin Hylecta (injection) treatment in March 2020. Recent 2023 annual CT of chest, abdomen and pelvis and annual brain MRI showed NED. Praying for NED forever!!